-
公开(公告)号：CR10656A
公开(公告)日：2009-05-22
申请号：CR10656
申请日：2009-03-06
Applicant: ABBOTT LAB
Inventor： WU CHENGBIN , DIXON RICHARD W , BELK JONATHAN P , YING HUA , ARGIRIADI MARIA A , CUFF CAROLYN A , HINTON PAUL , KUMAR SHANKAR , MELIM TERRY L , CHEN YAN
IPC: C07H21/00 , C07K14/00 , C07K16/00 , C12N1/15 , C12N1/16 , C12N1/21 , C12N5/00 , C12N5/04 , C12P21/00
Abstract: Proteinas de union a IL-13. Especificamente, la invencion se relaciona con anticuerpos que son quimericos, con injertos de CDR y anticuerpos humanizados. Los anticuerpos preferidos tienen gran afinidad por la hIL-13 y neutralizan la actividad de la hIIL-13 in vitro e in vivo. Un anticuerpo de la invencion puede ser un anticuerpo de longitud completa o una porcion de union al antigeno del mismo.
-
公开(公告)号：BRPI0716438A2
公开(公告)日：2014-03-04
申请号：BRPI0716438
申请日：2007-09-07
Applicant: ABBOTT LAB
Inventor： WU CHENGBIN , DIXON RICHARD W , BELK JONATHAN P , YING HUA , ARGIRIADI MARIA A , CUFF CAROLYN A , HINTON PAUL R , KUMAR SHANKAR , MELIN TERRY L , CHEN YAN
Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.
-
公开(公告)号：NZ599144A
公开(公告)日：2013-10-25
申请号：NZ59914407
申请日：2007-09-07
Applicant: ABBOTT LAB
Inventor： WU CHENGBIN , DIXON RICHARD W , BELK JONATHAN P , YING HUA , ARGIRIADI MARIA A , CUFF CAROLYN A , HINTON PAUL R , KUMAR SHANKAR , MELIM TERRY L , CHEN YAN
Abstract: 599144 Disclosed is a binding protein that possesses an antigen binding domain, said binding protein capable of binding IL-13, said antigen binding domain comprising six CDRs: CDR-H1 (TSDMGVD), CDR-H2 (HIWWDDVKRYNPALKS), CDR-H3 (TVSSGYIYYAMDY), CDR-L1 (RASQDIRNYLN), CDR-L2 (YTSKLHS or YTSMKPR), and CDR-L3 (QQGNTLPLT or QQGLTPPLT).
-
公开(公告)号：CR20130155A
公开(公告)日：2013-05-23
申请号：CR20130155
申请日：2013-04-03
Applicant: ABBOTT LAB
Inventor： LACY SUSAN E , FUNG EMMA , BELK JONATHAN P , DIXON RICHARD W , ROGUSKA MICHAEL , HINTON PAUL R , KUMAR SHANKAR
IPC: C07K16/00
Abstract: Proteínas de unión a IL-12 p40, en particular anticuerpos que se unen a la interleuquina-12 humana (hIL-12) y/o IL-23 humana (hIL-23). Específicamente, la invención se relaciona con anticuerpos que son quiméricos, con injertos de CDR y anticuerpos humanizados.
-
公开(公告)号：CR20130149A
公开(公告)日：2013-05-23
申请号：CR20130149
申请日：2013-04-03
Applicant: ABBOTT LAB
Inventor： LACY SUSAN E , FUNG EMMA , BELK JONATHAN P , DIXON RICHARD W , ROGUSKA MICHAEL , HINTON PAUL R , KUMAR SHANKAR
IPC: C07K16/00
Abstract: Proteínas de unión a IL-12 p40, en particular anticuerpos que se unen a la interleuquina-12 humana (hIL-12) y/o IL-23 humana (hIL-23). Específicamente, la invención se relaciona con anticuerpos que son quiméricos, con injertos de CDR y anticuerpos humanizados.
-
Patent Agency Ranking
公开(公告)号：NO20091411L
公开(公告)日：2009-05-22
申请号：NO20091411
申请日：2009-04-07
Applicant: ABBOTT LAB
Inventor： HINTON PAUL R , BELK JONATHAN P , DIXON RICHARD W , KUMAR SHANKAR , WU CHENGBIN , YING HUA , ARGIRIADI MARIA A , CUFF CAROLYN A , MELIM TERRY L , CHEN YAN
Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.
-
公开(公告)号：MX2009002554A
公开(公告)日：2009-03-20
申请号：MX2009002554
申请日：2007-09-07
Applicant: ABBOTT LAB
Inventor： HINTON PAUL R , DIXON RICHARD W , BELK JONATHAN P , KUMAR SHANKAR , WU CHENGBIN , ARGIRIADI MARIA A , YING HUA , CUFF CAROLYN A , MELIM TERRY L , CHEN YAN
Abstract: La presente invención comprende proteínas de enlace lL 13. Específicamente la presente invención se refiere a anticuerpos que son anticuerpos quiméricos, injertados con CDR y humanizados. Los anticuerpos preferidos tienen alta afinidad para hlL-13 y neutralizan la actividad hlL-13 in vitro e in vivo. Un anticuerpo de la presente invención puede ser un anticuerpo de longitud total o una parte de enlace de antígeno el mismo. También se proporciona un método para utilizar los anticuerpos de la presente invención. Los anticuerpos o partes de anticuerpo de la presente invención son útiles para detectar hlL-13 o para inhibir la actividad de hlL-13, por ejemplo en un sujeto humano que padece de un trastorno en el cual la actividad de hTL-13 es perjudicial.
-
公开(公告)号：AU2007351514A1
公开(公告)日：2008-10-23
申请号：AU2007351514
申请日：2007-09-07
Applicant: ABBOTT LAB
Inventor： KUMAR SHANKAR , CHEN YAN , BELK JONATHAN P , WU CHENGBIN , DIXON RICHARD W , ARGIRIADI MARIA A , CUFF CAROLYN A , YING HUA , MELIM TERRY L , HINTON PAUL R
IPC: C07K14/00 , C07H21/00 , C07K16/00 , C12N1/00 , C12N1/15 , C12N1/16 , C12N1/21 , C12N5/00 , C12N5/04 , C12N5/06 , C12P21/00
Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.
-
公开(公告)号：MX2007016401A
公开(公告)日：2008-02-20
申请号：MX2007016401
申请日：2006-06-29
Applicant: ABBOTT LAB
Inventor： HINTON PAUL R , ROGUSKA MICHAEL , DIXON RICHARD W , LACY SUSAN E , FUNG EMMA , BELK JONATHAN P , KUMAR SHANKAR
IPC: C07K14/715
Abstract: La presente invencion se refiere a proteinas de union IL-12p40, particularmente anticuerpos que unen interleucina-12 humana (hlL-12) y/o IL-23 humana (hlL-23). Especificamente, la invencion se refiere a anticuerpos que son quimericos, anticuerpos CDR-injertados y humanizados. Los anticuerpos preferidos tienen alta afinidad para hlL-12 y/o hlL-23 y neutralizar la actividad de hlL-12 y/o hlL-23 in vitro e in vivo. Un anticuerpo de la invencion puede ser un anticuerpo de longitud completa o una porcion de union de antigeno del mismo. Tambien se proporcionan metodos para hacer y utilizar los anticuerpos de la invencion. Los anticuerpos, o porciones de anticuerpos de la invencion, son utiles para detectar hlL-12 y/o hlL-23 y para inhibir la actividad de hlL-12 y/o hlL-23, por ejemplo, en un sujeto ser humano que sufre de un trastorno en donde la actividad de hlL-12 y/o hlL-23 es danina.
-
公开(公告)号：CA2612239A1
公开(公告)日：2007-01-11
申请号：CA2612239
申请日：2006-06-29
Applicant: ABBOTT LAB
Inventor： LACY SUSAN E , FUNG EMMA , BELK JONATHAN P , KUMAR SHANKAR , ROGUSKA MICHAEL , HINTON PAUL R , DIXON RICHARD W
IPC: C12N15/13 , A61K35/12 , A61K39/395 , A61P37/02 , C07K14/54 , C07K14/715 , C07K16/24 , C07K17/02 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/63 , C12P21/00
Abstract: The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL- 23). Specifically, the invention relates to antibodies that are chimeric, CD R grafted and humanized antibodies. Preferred antibodies have high affinity fo r hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or a n antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.
-
-
-
-
-
-
-
-
-
Search Results
37
records
(took 0.023 seconds)
